Document is current
Any future updates will be listed below
-
Authors
Parrondo, Ricardo D. https://orcid.org/0000-0002-9314-9933
Ailawadhi, Sikander https://orcid.org/0000-0002-8377-8111
Knopf, Betsy R.
Zimmerman, Ashley
Kasik, Carly J.
Chapin, Dustin
Heslop, Keisha
Roy, Vivek https://orcid.org/0000-0002-5950-4620
Paulus, Aneel https://orcid.org/0000-0001-8765-9649
Chanan-Khan, Asher A.
-
Funding
Funding for this research was provided by:
Foundation for the National Institutes of Health (RO1 CA233790-04)
- License Information
-
More Information
Article History
Received: 12 December 2025
Revised: 25 February 2026
Accepted: 25 March 2026
First Online: 7 May 2026
Competing interests
: BRK, AZ, CJK, DC, AP, and VR have no conflicts of interest to declare. RDP serves on the advisory board for Sanofi Aventis, Bristol Myers Squibb and Astra Zeneca and has received research funding from Bristol Myers Squibb Foundation, Beigene, and GlaxoSmithKline. SA has provided consultancy for Celgene, Amgen, Janssen and Takeda, and has received research funding from Pharmacyclics, Cellectar and Janssen. AAC-K has received research funding from Xencor Pharmacyclics, Merck, Janssen, Ascentage and Millennium.
: The study protocol and all amendments were reviewed and approved by the Institutional Review Board at Mayo Clinic Florida (IRB #19-001475). The study was conducted in accordance with the International Conference on Harmonisation Good Clinical Practice guidelines, the principles originating from the Declaration of HelsInformed consentinki, and study site-specific regulations.
: All participants signed written informed-consent forms.
